Tempus Expands Moderna, Merck Collaboration for Individualized Cancer Therapy

MT newswire2026/10/07 13:00

09:00 AM EDT, 10/07/2026 (MT Newswires) -- Tempus (TEM) said Wednesday it expanded its multi-year collaboration with Moderna (MRNA) and Merck (MRK) to support the potential commercialization of intismeran autogene, an individualized cancer therapy being tested with Keytruda in melanoma and other cancers. Financial terms were not disclosed. Under the collaboration, Tempus will manage tumor tissue, blood sample collection, transfer for sequencing and provide next-generation sequencing services to support the therapy's design and manufacturing, it added. Tempus and Moderna shares were down 2.9% and 2.1%, respectively, in premarket activity.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Sector Update: Energy Stocks Rise Wednesday Afternoon

MT newswire•2026/10/14 17:51

Updated: 3-United Therapeutics reached a settlement, eliminating key litigation risks, Liquidia stock surged

路透社•2026/10/14 17:36

Developer Says Evernorth Is Better to XRP Than MicroStrategy to Bitcoin. Here’s why

TimesTabloid•2026/10/14 17:18

Lion Copper Receives Approval for Nasdaq Capital Market Listing

Bitget•2026/10/14 16:48